REPLIMUNE GROUP, INC. Selling, General and Administrative Expense
REPLIMUNE GROUP, INC. (REPL) reported Selling, General and Administrative Expense of $18.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-14
- REPLIMUNE GROUP, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $18.97M, a 41.77% decline year-over-year.
- REPLIMUNE GROUP, INC. selling, general and administrative expense for the quarter ending 2025-06-30 was $32.58M.
- REPLIMUNE GROUP, INC. selling, general and administrative expense for fiscal 2026 was $98.73M, a 36.79% increase from fiscal 2025.
- REPLIMUNE GROUP, INC. selling, general and administrative expense for fiscal 2025 was $72.18M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 12 month |
|---|---|---|
| 2026-06-30 | $18.97M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $98.73M 10-K · filed 2026-06-29 | |
| 2025-06-30 | $32.58M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $72.18M 10-K · filed 2026-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |